We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Collaboration to Bring Personalized Cancer Care to Singapore

By LabMedica International staff writers
Posted on 23 Nov 2014
A German company specializing in cancer diagnosis will be extending its expertise in personalized care to the health care market in Singapore.

New Oncology (Cologne, Germany) announced recently that it has entered into a collaboration agreement with the National Cancer Centre Singapore (Singapore). New Oncology will provide its NEOplus proprietary diagnostic platform for use at the [Sg] National Cancer Center.

NEOplus, which is based on next generation sequencing (NGS) technology, is an efficient, time-saving diagnostic assay that enables the parallel analysis of all therapy-relevant genomic alterations in minute amounts of paraffin embedded material. Within 10–15 working days, NEOplus reliably and with high sensitivity detects mutations, amplifications, deletions, and translocations in over 80 oncogenes, tumor suppressors, and microsatellite DNA in all solid tumor types. The medical report generated from the NEOplus results suggests suitable targeted therapies and an individualized recommendation for treatment if actionable genetic alterations are identified. In addition to treatment options, the report also provides information on relevant clinical trials.

“We are very pleased to work with NCCS, one of the most prestigious centers for research and treatment of cancer in Southeast Asia. We are looking forward to building a productive partnership with the National Cancer Center Singapore and consider this move to be a major milestone in our international business expansion,” said Dr. Andreas Jenne, CEO of New Oncology.

Related Links:

New Oncology
National Cancer Center Singapore


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Rapid Molecular Testing Device
FlashDetect Flash10

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more